Related references
Note: Only part of the references are listed.An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
Balazs Gyoerffy et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
Kazuma Kiyotani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo
Maria L. H. Vlaming et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Cancer Stem Cells in Solid Tumors: An Overview
Catherine Adell O'Brien et al.
SEMINARS IN RADIATION ONCOLOGY (2009)
Association of ATP-Binding Cassette, Sub-family C, Number 2 (ABCC2) Genotype with Pharmacokinetics of Irinotecan in Japanese Patients with Metastatic Colorectal Cancer Treated with Irinotecan Plus Infusional 5-Fluorouracil/Leucovorin (FOLFIRI)
Ken-ichi Fujita et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2008)
Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome
Pawel Surowiak et al.
VIRCHOWS ARCHIV (2007)
Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients
Verena Materna et al.
VIRCHOWS ARCHIV (2007)
ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome
Pawel Surowiak et al.
CLINICAL CANCER RESEARCH (2006)
High-dose methotrexate in pediatric acute lymphoblastic leukemia:: Impact of ABCC2 polymorphisms on plasma concentrations
Thomas Rau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells
Verena Materna et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis
VS Donnenberg et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination
JS Hulot et al.
PHARMACOGENETICS AND GENOMICS (2005)
Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDRI/P-gp, MRP2, and BCRP
P Kowalski et al.
MOLECULAR THERAPY (2005)
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance
P Surowiak et al.
BREAST CANCER RESEARCH (2005)
ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat
RL Qiu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
ABC-transporters: implications on drug resistance from microorganisms to human cancers
H Lage
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2003)
Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening
L Tabar et al.
LANCET (2003)
Share Paper
